Alnylam Pharmaceuticals reported quarterly EPS of $1.99, beating the Zacks Consensus Estimate of $1.43 by $0.56 per share, and reversing a year-ago loss of $0.01 per share. The earnings beat is a positive read-through for company fundamentals and likely supportive of the stock, though the article provides no revenue or guidance details.
Alnylam Pharmaceuticals reported quarterly EPS of $1.99, beating the Zacks Consensus Estimate of $1.43 by $0.56 per share, and reversing a year-ago loss of $0.01 per share. The earnings beat is a positive read-through for company fundamentals and likely supportive of the stock, though the article provides no revenue or guidance details.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
